Dergiler / Gülhane Tıp Dergisi / 2021 / Cilt: 63 - Sayı: 3

Long-term results of patients treated with bronchoscopic lung volume reduction

Sayfa
193–199
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

At 3 and 6 months, respectively, ΔCAT was −4.8±6 and −7.5±7.2 points, Δ6-MWD was+103.4±139 m and +160.8±149 m [endobronchial valve (EBV)], ΔFEV1 was +0.15±0.3 L and+0.21±0.3 L, ΔFVC was +0.44±0.7 L and +0.5±0.7 L, (all p<0.05), and ΔRV (residual volume) was−0.52±1.1 L and 0.32±1.5 L (p˃0.05).Conclusions: In our study, BLVR (EBV and coil) treatments were used in patients with severeto very severe emphysema in COPD, in appropriate indications and in selected cases, andstatistically significant well-being was observed in spirometric parameters in the first sixmonths after the procedure.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: Surgical and bronchoscopic treatments are tried to reduce hyperinflation togetherwith medical treatments in patients with chronic obstructive pulmonary disease (COPD) andemphysema.
📊
Temel Bulgular & Veri:Therefore, bronchoscopic lung volume reduction (BLVR) procedures can improvethe success of treatment and quality of life of patients.Methods: We investigated the efficacy and safety of BLVR treatment retrospectively.Demographic characteristics, modified Medical Research Council (mMRC) and COPDassessment test (CAT) questionnaires, 6-minute walking distance (6-MWD) and all pulmonaryfunction tests of the patients, who were treated with BLVR, were examined.
💡
Sonuç & Katkı:At 3 and 6 months, respectively, ΔCAT was −4.8±6 and −7.5±7.2 points, Δ6-MWD was+103.4±139 m and +160.8±149 m [endobronchial valve (EBV)], ΔFEV1 was +0.15±0.3 L and+0.21±0.3 L, ΔFVC was +0.44±0.7 L and +0.5±0.7 L, (all p<0.05), and ΔRV (residual volume) was−0.52±1.1 L and 0.32±1.5 L (p˃0.05).Conclusions: In our study, BLVR (EBV and coil) treatments were used in patients with severeto very severe emphysema in COPD, in appropriate indications and in selected cases, andstatistically significant well-being was observed in spirometric parameters in the first sixmonths after the procedure.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Aims: Surgical and bronchoscopic treatments are tried to reduce hyperinflation togetherwith medical treatments in patients with chronic obstructive pulmonary disease (COPD) andemphysema. Therefore, bronchoscopic lung volume reduction (BLVR) procedures can improvethe success of treatment and quality of life of patients.Methods: We investigated the efficacy and safety of BLVR treatment retrospectively.Demographic characteristics, modified Medical Research Council (mMRC) and COPDassessment test (CAT) questionnaires, 6-minute walking distance (6-MWD) and all pulmonaryfunction tests of the patients, who were treated with BLVR, were examined. The values beforethe procedure and the values at the third and sixth months after the procedure were analyzedstatistically.Results: Twenty-five patients were examined (one was female). Six patients (59±10.4 years,forced expiratory volume in 1 s (FEV1) 21.7±5.7% pred) were bronchoscopically treated withcoils, with a median of 9.33 (range 8-11) coils per procedure. Nineteen patients (65.8±6 years,FEV1 26.9±9% pred) were treated with valves, with a median 3.52 (range 3-4) valves perpatient. At 3 and 6 months, respectively, ΔCAT was −4.8±6 and −7.5±7.2 points, Δ6-MWD was+103.4±139 m and +160.8±149 m [endobronchial valve (EBV)], ΔFEV1 was +0.15±0.3 L and+0.21±0.3 L, ΔFVC was +0.44±0.7 L and +0.5±0.7 L, (all p<0.05), and ΔRV (residual volume) was−0.52±1.1 L and 0.32±1.5 L (p˃0.05).Conclusions: In our study, BLVR (EBV and coil) treatments were used in patients with severeto very severe emphysema in COPD, in appropriate indications and in selected cases, andstatistically significant well-being was observed in spirometric parameters in the first sixmonths after the procedure.

🔖

Bu Makaleye Atıf Yap

ÇAĞIN, A., DOGAN, D., TAŞÇI, C. (2021). Long-term results of patients treated with bronchoscopic lung volume reduction. Gülhane Tıp Dergisi, Cilt: 63 - Sayı: 3, 193–199. https://ajindex.com/articles/347970

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (13)

  1. GOLD. Guide to COPD Diagnosis, Management and Prevention: A Guide for Health Care Professionals Paperback. 2019. Available from: http://goldcopd.org/wpcontent/ uploads/2018/11/GOLD-2019-POCKET-GUIDEFINAL_ WMS.pdf 2. Gülşen A. Bronchoscopic Lung Volume Reduction: A 2018 Review and Update. Turk Thorac J. 2018
  2. Holloway RA, Donnelly LE. Immunopathogenesis of chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2013
  3. Rustagi N, Singh S, Dutt N, et al. Efficacy and Safety of Stent, Valves, Vapour ablation, Coils and Sealant Therapies in Advanced Emphysema: A Meta-Analysis. Turk Thorac J. 2019
  4. van Agteren JE, Hnin K, Grosser D, Carson KV, Smith BJ. Bronchoscopic lung volume reduction procedures for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017
  5. CD012158. 6. Davey C, Zoumot Z, Jordan S, et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet. 2015
  6. Gompelmann D, Sarmand N, Herth FJ. Interventional pulmonology in chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2017
  7. Yorgancıoğlu A, Polatlı M, Aydemir Ö, et al. KOAH değerlendirme testinin Türkçe geçerlilik ve güvenilirliği [Reliability and validity of Turkish version of COPD assessment test]. Tuberk Toraks. 2012
  8. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002
  9. Ambrosino N, Simonds A. The clinical management in extremely severe COPD. Respir Med. 2007
  10. GOLD, Global Initiative for Chronic Obstructive Lung Disease. 2017. Available from: https://goldcopd.org/ archived-reports/ 12. Herth FJF, Slebos DJ, Criner GJ, Shah PL. Endoscopic Lung Volume Reduction: An Expert Panel Recommendation - Update 2017. Respiration. 2017
  11. Deslée G, Mal H, Dutau H, et al. Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial. JAMA. 2016
  12. Sciurba FC, Criner GJ, Strange C, et al. Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. JAMA. 2016
  13. Klooster K, Hartman JE, Ten Hacken NH, Slebos DJ. One- Year Fol